People with Absorption Issues If you have conditions like pernicious anemia or Crohns disease, you may need more frequent injections to compensate for poor absorption
Why arent prefilled syringes available in Canada
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Our comprehensive peptide guides give you evidence-based information on mechanisms, dosing, combinations, and troubleshooting
Initial Loading Dose Protocol For severe deficiency, the first dose is usually 1,000 mcg given intramuscularly
Note: Picture shows insulin syringe
